- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Stephen Heitner Outlines the Next Steps After MAVERICK-HCM Study Findings
Based off the rich data available on mavacamten efficacy within subsets of patients with non-obstructive HCM, researchers have designed the next phase of study on this select group, said Stephen Heitner, MD, director of Clinical Trials and director of the Hypertrophic Cardiomyopathy Center at the Oregon Health and Science University.
Based off the rich data available on mavacamten efficacy within subsets of patients with non-obstructive HCM, researchers have designed the next phase of study on this select group, said Stephen Heitner, MD, director of Clinical Trials and director of the Hypertrophic Cardiomyopathy Center at the Oregon Health and Science University.
Transcript
Can you discuss the results from MAVERICK-HCM? How will the insights from this study drive the next phase of research in non-obstructive HCM?
MAVERICK—we’re super excited to have finished. That’s looking at, I think there were 59 patients in this placebo-controlled multi-site study, looking at the impact of mavacamten in patients with non-obstructive HCM. You know this is a very ... challenging group of patients. What we have seen–you know this is a very high-level result–is firstly, that the NT-proBNP, which is a measure of left ventricular filling–a lot of these patients have heart failure with preserved ejection fraction as a result of hypertrophic cardiomyopathy. So, their NT-proBNPs was significantly reduced after 16 weeks of mavacamten therapy, which is incredible. What we’re doing right now is kind of going through the very rich data that we have from that to look at where mavacamten will be most useful. So, which subset of those patients mavacamten will be applicable for. Based on that, we’re going to be designing the next phase of study, which is the phase 3 in non-obstructive HCM patients to better inform and hopefully show that this is an effective therapy in these individuals.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
